TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage ...
In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. The Company received a $5.0 ...
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ...
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...
“Choosing wisely” in oncology: The example of surveillance positron emission tomography-computed tomography (PET-CT) for patients with colorectal cancer (CRC) treated with curative intent. This is an ...
Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide ...
A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, "WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?" Novel biological ...
Researchers at the University of Illinois, Urbana-Champaign, developed an approach using blue light to activate the Wnt signaling pathway in frog embryos. The pathway plays a wide variety of roles in ...
Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from chronic liver diseases, including hepatitis B or C infections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results